|
|
|
| USPHS Study 26:
Highly intermittent |
||
| short-course
treatment of LTBI |
||
|
|
|
|
|
|
|
|
|
|
| • | Patients with
LTBI at high risk for |
||||||||
| developing
active disease will receive INH |
|||||||||
| for 9 months
OR once weekly
INH/rifapentine |
|||||||||
| for
12 doses (3INH/RPT) |
|||||||||
| • | Main study
outcome: rate of development of |
||||||||
| active
tuberculosis |
|||||||||
| • | Almost ~3,000
enrolled to date, sample size |
||||||||
| = 8,000 total
or 4,000 per arm |
|||||||||